About Wockhardt Limited

Overview 

 

Wockhardt Limited is an Indian pharmaceutical and biotechnology company with its head office in Mumbai, Maharashtra, India. Founded by Dr. Habil Khorakiwala in the 1960s, Wockhardt has a presence in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs) and Super Speciality Hospitals. The company has full-fledged operations in India, USA, UK, Ireland and France, and a marketing presence in emerging markets like Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.

 

The company’s super specialty hospitals offer treatment and care facilities in cardiology, neurosurgery, orthopedics, critical care, oncology, nephrology, urology, among others.

 

As of 31st March 2016, the company (as per its website):

  • Reported primary sales revenues USD 673 million (?4,461 crore), out of which:

    • International business accounted for 68% of total sales

    • Domestic business accounted for 32% of total sales

  • Had 14 manufacturing facilities strategically located across India, US and Europe

  • Had 12 contract manufacturing facilities strategically located throughout Europe and Asia

  • Had 3 R&D Centers (India, UK & USA)

    • 822 research professionals including 99 doctorates

    • 15% of total sales in R&D investments

    • Was the only company in the world to have 5 experimental antibiotic drugs with QIDP status granted by US FDA

  • Enjoyed the 4th and 5th position in Pain Management and Vaccines in India

  • Had 7 of its brands among the Top 300 brands in the India Pharma Market (IPM)

 

Other Highlights

 

  • The largest Indian generics company in the United Kingdom (Wockhardt UK)

  • The #1 branded generics company in Ireland (Wockhardt's Pinewood)

  • The 4th company in the world to develop recombinant insulin from concept to market stage (Wosulin)

  • The 1st company in the world (after the originator) to develop and market glargine, a long acting insulin analogue (Glaritus)

  • Awarded (4 times in a row) the prestigious Patent Award by the Government of India, for the Maximum Number of Patent Filings & Grants from India

  • Recipient of the prestigious Worldstar Award, the highest recognition in packaging

  • A Business Superbrand for 2 consecutive years

  • Associated with Partners Harvard Medical International, the international arm of Harvard Medical School, USA (Wockhardt Hospitals)

 

Wockhardt Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).

 

Wockhardt Limited at-a-glance

 

  • Employees 10,000+
  • Turnover (31 March, 2015) ~USD 673m
  • Major Markets India, USA,
    UK, Ireland,
    France
  • Manufacturing Facilities 14
  • Contract Manufacturing Facilities 12
  • R&D Centers 3
  • Patents Filed 2,579
  • Patents Granted 441
  • ANDAs Filed (2015-16) 17
  • ANDAs Pending Approval 84
  • QUIDPs1 Filed in 2015-16 3

 

 

 

Approvals

US FDA, UK MHRA, etc.

*Source:

Annual Report 2015-16

Company Website

Company Fact Sheet

 

History

 

Prior to Wockhardt’s formation in 1967 by Dr. Habil Khorakiwala, Worli Chemical Works was acquired by the founder’s father, Mr. Fakhruddin T Khorakiwala, in 1959. The company was subsequently incorporated as Wockhardt Pvt. Ltd. and Wockhardt Ltd. (1999).
 

The company’s long term outlook continues to look optimistic due to:

  • The growth of the global pharmaceutical industry

  • The company’s sustained focus on R&D, especially complex generics, biotechnology and NCE programs 

  • Expanding reach in regulated markets and sustained efforts to enhance presence in emerging markets like Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait

  • Increasing number of niche and complex generic products in the pipeline

 

Milestones

 

The company has not shared this information

 

BOARD OF DIRECTORS

  • Founder, Chairman & Group CEO: Dr. Habil Khorakiwala

  • Non-Executive Independent Director: Mr. Shekhar Datta

  • Non-Executive Independent Director: Mr. Aman Mehta

  • Non-Executive Independent Director: Mr. DS Brar

  • Non-Executive Independent Director: Dr. Sanjay Baru

  • Non-Executive Independent Director: Mrs. Tasneem Mehta

  • Non-Executive Independent Director: Mr. Baldev Raj Arora

  • Executive Director: Dr. Huzaifa Khorakiwala

  • Managing Director: Dr. Murtaza Khorakiwala

 

CONTACTS

 

CORPORATE OFFICE

Wockhardt Limited

Wockhardt Towers

Bandra Kurla Complex, Bandra (East)

Mumbai-400051

Maharashtra

India

 

Website: http://www.wockhardt.com/

Tel: +91 22 2653 4444

Fax: +91 22 2652 3905

+91 22 2652 2929

 

INVESTOR CONTACT

Tel: +91 022 2653 4444 Ext. 6219 (Board No.)

Tel: +91 022 2659 6219 (Direct)

Fax: +91 022 2653 4242

Email: investorrelations@wockhardt.com

USA OFFICE

Wockhardt USA LLC

20 Waterview Boulevard, 3rd Floor

Parsippany NJ 07054-1271

USA

 

Tel: +1 973 2574960

Fax: +1 973 2574961

 

Morton Grove Pharmaceuticals Inc.

6451 Main Street

Morton Grove, Illinois 60053-2633

USA

 

Tel: +1 847 9675600

Fax: +1 847 9672211

 

SWITZERLAND

Wockhardt Bio AG

Grafenauweg 6

6300 Zug

Switzerland

 

Tel: +41 41 7275220

Fax: +41 41 7275221

UNITED KINGDOM

Wockhardt UK Limited

Ash Road North

Wrexham Industrial Estate

Wrexham, LL13 9UF Wales

United Kingdom

 

Tel: +44 1978 661261

Fax: +44 1978 660130

IRELAND

Pinewood Healthcare

Ballymacarbry, Clonmel

Co. Tipperary

 

Tel: +353 52 6186000

Fax: +353 52 6136311

FRANCE

Laboratoires Negma

Buroplus 3

Za De La Clef St Pierre

1 Bis Avenue Jean D'alembert

Cs 80563

78996 Elancourt Cedex

France

 

Tel: (0033) 161 3720 00

Fax: (0033) 161 3720 30

 

Qualified Infectious Disease Product (QIDP). The QIDP status is granted to drugs that act against pathogens which have a high degree of unmet needs in their treatment. It allows for fast track review of the drug application by the US FDA, and paves way for an early launch.



Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...